BNP Paribas Financial Markets’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-182
| Closed | -$96 | – | 6199 |
|
|
2025
Q4 | $96 | Buy |
+182
| New | +$96 | ﹤0.01% | 5616 |
|
|
2024
Q4 | – | Sell |
-182
| Closed | -$240 | – | 5598 |
|
|
2024
Q3 | $240 | Hold |
182
| – | – | ﹤0.01% | 4033 |
|
|
2024
Q2 | $1.38K | Hold |
182
| – | – | ﹤0.01% | 3843 |
|
|
2024
Q1 | $1.64K | Hold |
182
| – | – | ﹤0.01% | 3828 |
|
|
2023
Q4 | $1.95K | Hold |
182
| – | – | ﹤0.01% | 3810 |
|
|
2023
Q3 | $1.09K | Hold |
182
| – | – | ﹤0.01% | 3743 |
|
|
2023
Q2 | $1.26K | Hold |
182
| – | – | ﹤0.01% | 3752 |
|
|
2023
Q1 | $2.86K | Sell |
182
-41
| -18% | -$807 | ﹤0.01% | 3619 |
|
|
2022
Q4 | $4.46K | Hold |
223
| – | – | ﹤0.01% | 3669 |
|
|
2022
Q3 | $3.98K | Sell |
223
-171
| -43% | -$3.67K | ﹤0.01% | 4273 |
|
|
2022
Q2 | $8.74K | Sell |
394
-734
| -65% | -$16.4K | ﹤0.01% | 3761 |
|
|
2022
Q1 | $31.4K | Sell |
1,128
-591
| -34% | -$21.5K | ﹤0.01% | 3652 |
|
|
2021
Q4 | $78K | Buy |
1,719
+1,184
| +221% | +$79.7K | ﹤0.01% | 3658 |
|
|
2021
Q3 | $44.6K | Buy |
535
+302
| +130% | +$25K | ﹤0.01% | 3541 |
|
|
2021
Q2 | $22.1K | Buy |
+233
| New | +$27.6K | ﹤0.01% | 3510 |
|
|
2020
Q2 | – | Hold |
0
| – | -$12 | – | 4410 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 4280 |
|
|
2019
Q4 | – | Sell |
-5
| Closed | -$517 | – | 4382 |
|
|
2019
Q3 | $485 | Hold |
5
| – | – | ﹤0.01% | 4421 |
|
|
2019
Q2 | $646 | Sell |
5
-4
| -44% | -$618 | ﹤0.01% | 4391 |
|
|
2019
Q1 | $1.43K | Buy |
9
+8
| +800% | +$1.19K | ﹤0.01% | 4134 |
|
|
2018
Q4 | $58 | Hold |
1
| – | – | ﹤0.01% | 4241 |
|
|
2018
Q3 | $237 | Hold |
1
| – | – | ﹤0.01% | 4366 |
|
|
2018
Q2 | $2.31K | Buy |
+1
| New | +$2.54K | ﹤0.01% | 4233 |
|
|
2014
Q3 | – | Sell |
-2
| Closed | -$3.2K | – | 4321 |
|
|
2014
Q2 | $3.2K | Buy |
2
+1
| +100% | +$1.98K | ﹤0.01% | 2841 |
|
|
2014
Q1 | $3.15K | Sell |
1
-1
| -50% | -$2.49K | ﹤0.01% | 2531 |
|
|
2013
Q4 | $3.77K | Buy |
+2
| New | +$4.58K | ﹤0.01% | 3288 |
|
|
2013
Q3 | – | Sell |
-8
| Closed | -$75K | – | 2750 |
|
|
2013
Q2 | $75K | Buy |
+8
| New | +$61.6K | ﹤0.01% | 2593 |
|
Other funds holding ONCT
BNP Paribas Financial Markets's ONCT Position: Q1 2026 in Review
BNP Paribas Financial Markets sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2026, closing a stake of 182 shares — an estimated $96 sold.
BNP Paribas Financial Markets first reported a position in ONCT in Q2 2013 and held it in 25 quarters. The position peaked at $78K in Q4 2021. 1 fund tracked by Wall St. Rank holds ONCT as of Q1 2026.
- BNP Paribas Financial Markets reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
- BNP Paribas Financial Markets sold 182 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2026, an estimated $96.
- BNP Paribas Financial Markets first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
- BNP Paribas Financial Markets's Oncternal Therapeutics, Inc. Common Stock position peaked at $78K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.